Under the Radar: Moderna Stock Rises on Flu-Shot Recommendation -- WSJ

Dow Jones06-19

By Peter Loftus

Moderna shares rose 3.5% Thursday after an advisory committee voted to recommend the U.S. Food and Drug Administration approve the biotech's proposed new flu shot for people 50 and older.

The FDA had initially declined to consider Moderna's application for the shot's approval, but then agreed to review it after Moderna amended it. The advisory committee vote in favor of the vaccine isn't binding, but the FDA generally follows such recommendations. A decision is expected by early August.

Shares of Moderna, which is trying to expand beyond Covid-19 vaccines, closed at their highest level since September 2024. The stock is up 39% over the past six trading days.

This item is part of a Wall Street Journal live coverage event. The full stream can be found by searching P/WSJL (WSJ Live Coverage).

(END) Dow Jones Newswires

June 18, 2026 17:30 ET (21:30 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment